// App-Quantinova.ai

: Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial

Researchers

Presenter

  • Eric White

Principal Investigators

  • Vincent Cottin

  • Martin Kolb

  • Toby M Maher

  • Carina Ittrich

  • Claudia Diefenbach

  • Klaus B Rohr

  • Manuel Quaresma

  • Bruno Crestani

Medical Centers

  • University of Michigan, Division of Pulmonary & Critical Care Medicine, Ann Arbor, MI, United States,

  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France,

  • McMaster University and St. Joseph’s Healthcare, Hamilton, Ontario, Canada

  • National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Hôpital Bichat, Pneumologie, Paris, France

Locations

  • United States

  • France

  • Canada

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

  • Sildenafil citrate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved